This week's happenings in the business world of psychedelic treatments
Psychedelics Takes A Seat On the World Stage
Every year world leaders come together to discuss the global economy at the World Economic Forum’s annual gathering in Davos Switzerland. This small town in the Alps has become the place where the smartest people on the planet come together to discuss solutions to the world's economic problems and issues...
MindMed Expenses Rise As Company Files $100 Million Offering
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) reported its financial results for the first quarter ending March 31, 2022. At this time, MindMed does not have any revenue to report...
Atai Gives Business Update, Remains Well Funded
An earnings and business update video call today for Atai Life Sciences (NASDAQ-ATAI), a clinical-stage biopharmaceutical company that acquires, incubates and develops innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders, featured Atai Life Sciences CEO and Co-Founder Florian Brand; CSO and Co-Founder Srinivas Rao; and CFO Greg Weaver, as well as two analysts doing questions and answers during the call...
Mid-year Momentum Firing up a Psychedelics Rush
Psychedelics are finally, carefully, hitting its stride this year. Even with a dour stock market beating it up, mid-year indicators of a jazzed-up emerging psychedelics industry that is finding its way are everywhere...
Beckley Foundation Co-Founder Creates Psychedelic Retreats in Jamaica
A new psilocybin-focused holistic wellbeing company called Beckley Retreats is officially launching from the founder of the Beckley Foundation, the drug policy reform and scientific research institution...
In Other News
GH Research PLC (Nasdaq: GHRS) reported financial results for the first quarter ended March 31, 2022 and gave updates on its business. Cash was $270.8 million as of March 31, 2022, compared to $276.8 million as of December 31, 2021. We believe that our existing cash will be sufficient for us to fund our operating expenses and capital expenditure requirements into 2025.GH001 is our proprietary inhalable 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) product candidate. Read more here.
Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) is pleased to provide an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) (NCT04504734) to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19. Read more here.
Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) announced today the completion of the world’s first ketamine treatment study for behavioral addictions. The behavioral addictions included in the study were Gambling Disorder, Internet Gaming Disorder, Binge Eating Disorder and Compulsive Sexual Behavior. Read more here.
May 20-26: Medical Psychedelic Series – Davos Switzerland
May 23-26: H.C. Wainwright Global Investment Hybrid Conference  Miami FL
Oct 12-16: Horizons Perspectives on Psychedelics NYC, More here
Nov 3-5: Wonderland Miami FL, More here
Facebook Twitter Instagram YouTube RSS
You are receiving this newsletter because you opted-in on our website, purchased a financial report, or registered for a GMR event.
Share your feedback | Unsubscribe
Back to Top